aid: generalproximity name: General Proximity description: General Proximity is a biotechnology company pioneering next-generation "proximity medicines" that control biological processes by inducing proximity between molecular targets. Its multi-target OMNITAC platform is used to discover and advance novel therapeutics, including an oncology collaboration with Daiichi Sankyo. The company is backed by investors including Felicis and Y Combinator, and has drawn investment from Freemind and Daewoong Pharmaceutical. This is a company profile in the API Evangelist network; General Proximity is a drug-discovery company and does not publish a public API, developer portal, or machine-readable API artifacts at this time. url: https://raw.githubusercontent.com/api-evangelist/generalproximity/refs/heads/main/apis.yml x-type: company x-source: vc-portfolio x-backed-by: - felicis x-tier: stub x-tier-reason: portfolio-lead x-industry: biotechnology accessModel: pricing: unknown onboarding: unknown trial: false try_now: false public: false label: Unknown confidence: low source: [] generated: '2026-07-22' method: derived image: https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6768b7b8dd575365a0592904_logo_square%20256.png specificationVersion: '0.20' created: '2026-07-17' modified: '2026-07-19' tags: - Company - Biotechnology - Pharmaceuticals - Drug Discovery - Proximity Medicines - Oncology - Therapeutics - Life Sciences apis: [] maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io common: - type: Website url: https://www.generalproximity.bio - type: Blog url: https://generalproximity.substack.com/ - type: Twitter url: https://x.com/proxbio - type: LinkedIn url: https://www.linkedin.com/company/generalproximity/ - type: Careers url: https://www.generalproximity.bio/careers - type: News url: https://www.generalproximity.bio/news - type: Team url: https://www.generalproximity.bio/team x-enrichment: date: '2026-07-19' status: backfilled pass: local-v1 note: backfilled from .gitignore signal + verified work evidence